Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|10|1105-1137

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.10, 2004-04, pp. : 1105-1137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes

By MacAulay Katrina   Woodgett James R  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 10, 2008-10 ,pp. : 1265-1274

Informa Healthcare

Access to resources Recommend Favorite

Development of 11&bgr; -HSD1 Inhibitors for the Treatment of Type 2 Diabetes

By  

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 7, 2008-06 ,pp. : 702-710

Bentham Science Publishers

Access to resources Recommend Favorite

Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

By Eldar-Finkelman Hagit   Ilouz Ronit  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1511-1519

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Glucose-6-phosphatase inhibitors for the treatment of Type 2 diabetes

By Westergaard Niels   Madsen Peter  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1429-1441

Informa Healthcare

Access to resources Recommend Favorite